Virios Therapeutics (VIRI) Competitors $4.85 +0.02 (+0.31%) As of 08/1/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock VIRI vs. ARCT, GLUE, HUMA, CYRX, INBX, TNXP, FHTX, CADL, AURA, and ABEOShould you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include Arcturus Therapeutics (ARCT), Monte Rosa Therapeutics (GLUE), Humacyte (HUMA), CryoPort (CYRX), Inhibrx Biosciences (INBX), Tonix Pharmaceuticals (TNXP), Foghorn Therapeutics (FHTX), Candel Therapeutics (CADL), Aura Biosciences (AURA), and Abeona Therapeutics (ABEO). These companies are all part of the "pharmaceutical products" industry. Virios Therapeutics vs. Its Competitors Arcturus Therapeutics Monte Rosa Therapeutics Humacyte CryoPort Inhibrx Biosciences Tonix Pharmaceuticals Foghorn Therapeutics Candel Therapeutics Aura Biosciences Abeona Therapeutics Virios Therapeutics (NASDAQ:VIRI) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings. Do analysts prefer VIRI or ARCT? Virios Therapeutics presently has a consensus price target of $5.00, indicating a potential upside of 3.09%. Arcturus Therapeutics has a consensus price target of $54.00, indicating a potential upside of 339.02%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Arcturus Therapeutics is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the media prefer VIRI or ARCT? In the previous week, Arcturus Therapeutics had 3 more articles in the media than Virios Therapeutics. MarketBeat recorded 3 mentions for Arcturus Therapeutics and 0 mentions for Virios Therapeutics. Arcturus Therapeutics' average media sentiment score of 1.65 beat Virios Therapeutics' score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Virios Therapeutics Neutral Arcturus Therapeutics Very Positive Which has higher valuation and earnings, VIRI or ARCT? Virios Therapeutics has higher earnings, but lower revenue than Arcturus Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-17.96Arcturus Therapeutics$131.27M2.54-$80.94M-$2.53-4.86 Is VIRI or ARCT more profitable? Virios Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -47.47%. Arcturus Therapeutics' return on equity of -27.41% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% Arcturus Therapeutics -47.47%-27.41%-19.01% Do insiders & institutionals believe in VIRI or ARCT? 9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Comparatively, 16.6% of Arcturus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, VIRI or ARCT? Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500. SummaryArcturus Therapeutics beats Virios Therapeutics on 13 of the 16 factors compared between the two stocks. Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRI vs. The Competition Export to ExcelMetricVirios TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$93.40M$771.23M$5.49B$9.52BDividend YieldN/A4.84%4.73%4.09%P/E Ratio-17.961.3428.7823.81Price / SalesN/A25.68372.2066.04Price / CashN/A19.5635.4557.96Price / Book24.256.768.275.54Net Income-$5.30M-$3.67M$3.25B$259.28M7 Day Performance1.68%-4.45%-3.70%-4.64%1 Month Performance-2.02%0.35%4.34%4.41%1 Year Performance2,466.14%16.03%25.90%17.95% Virios Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRIVirios TherapeuticsN/A$4.85+0.3%$5.00+3.1%+2,247.1%$93.40MN/A-17.965Upcoming EarningsARCTArcturus Therapeutics3.0347 of 5 stars$13.79+2.1%$54.00+291.6%-43.0%$366.13M$152.31M-5.45180Positive NewsGLUEMonte Rosa Therapeutics1.2679 of 5 stars$5.83-1.9%$15.33+163.0%+9.6%$365.37M$75.62M72.8890HUMAHumacyte1.7073 of 5 stars$2.30-1.3%$11.71+409.3%-73.5%$361.43M$1.57M-3.33150News CoverageGap DownCYRXCryoPort2.1548 of 5 stars$6.71-6.7%$10.88+62.1%-16.4%$360.49M$228.38M-2.871,186Upcoming EarningsINBXInhibrx Biosciences1.3548 of 5 stars$22.12-9.5%N/A+48.2%$353.94M$200K0.19166TNXPTonix Pharmaceuticals3.4312 of 5 stars$45.10-3.9%$70.00+55.2%-24.9%$345.13M$10.09M0.0050Analyst RevisionGap DownFHTXFoghorn Therapeutics2.4956 of 5 stars$6.10-0.5%$12.13+98.8%-23.3%$341.70M$22.60M-4.49120Upcoming EarningsGap DownCADLCandel Therapeutics2.1899 of 5 stars$6.57-2.5%$22.00+234.9%+13.5%$337.69M$120K-4.9060Gap DownAURAAura Biosciences1.556 of 5 stars$6.77+0.9%$22.00+225.0%-31.6%$337.30MN/A-3.5650Gap DownABEOAbeona Therapeutics3.8538 of 5 stars$6.75+2.4%$19.25+185.2%+34.9%$337.13MN/A-5.3190News Coverage Related Companies and Tools Related Companies Arcturus Therapeutics Alternatives Monte Rosa Therapeutics Alternatives Humacyte Alternatives CryoPort Alternatives Inhibrx Biosciences Alternatives Tonix Pharmaceuticals Alternatives Foghorn Therapeutics Alternatives Candel Therapeutics Alternatives Aura Biosciences Alternatives Abeona Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRI) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
